Results
Meta-analytic comparison of prothrombin complex concentrate with fresh frozen plasma for warfarin reversal. The search strategy identified 5,026 unique articles, of which 13 studies (n¼2,114 participants) met the inclusion criteria for review. There were 5 randomized controlled trials, 1 prospective cohort study, and 7 retrospective cohort studies. Four studies investigated reversal in patients who underwent an emergency surgery or invasive procedure, 8 studies assessed patients with warfarinassociated bleeding, and 1 study assessed both warfarin-associated bleeding and emergency surgery. The mean age of the patients ranged from 34 to 78 years. Eight studies assessed 4-factor prothrombin complex concentrate, 3 studies assessed 3-factor prothrombin complex concentrate, 1 study assessed both 4-and 3-factor prothrombin complex concentrate, and 1 study did not specify the type of prothrombin complex concentrate used. The randomized controlled trials were at low or unclear risk of bias for most categories, although all were at high risk of bias for blinding, 3 had high risk of bias for selective outcome reporting, and 2 were categorized as high risk for "other bias." The overall risk of bias for the observational trials was judged as moderate for most, with the exception of 2 that were deemed as being at serious risk. 
METHODS

DATA EXTRACTION AND SYNTHESIS
Two reviewers independently selected studies, extracted data, and assessed study quality, with discrepancies resolved by consensus or a third reviewer. Data were extracted with a standardized form. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) for categorical outcomes were generated with a Mantel-Haenszel randomeffects model and reanalyzed with a fixed-effects model. Continuous When prothrombin complex concentrate was compared with fresh frozen plasma, there was a statistically significant improvement in overall mortality, rapid international normalized ratio (INR) reduction, time to INR correction, and incidence of congestive heart failure or volume overload (Table) . Clinical hemostasis, packed RBC transfusion, and thromboembolic events were not statistically different between groups.
Subgroup analysis by prothrombin complex concentrate composition demonstrated that the mortality benefit was observed only with 4-factor prothrombin complex concentrates (OR 0.53; 95% CI 0.34 to 0.84). There was no significant difference noted with the 3-factor prothrombin complex concentrates (OR 3.55; 95% CI 0.12 to 105.82). When subgrouped by indication for anticoagulant reversal, prothrombin complex concentrates yielded lower mortality than fresh frozen plasma for intracranial bleeding (OR 0.42; 95% CI 0.19 to 0.95) but no significant mortality difference for extracranial bleeding (OR 0.43; 95% CI 0.13 to 1.48) or a need for emergency surgery (OR 0.36; 95% CI 0.09 to 1.39).
Commentary
3 Studies have demonstrated that major bleeding events occur in up to 2% to 3% of patients receiving vitamin K antagonists every year, with case fatality rates approaching 13%. 4 Additionally, patients receiving vitamin K antagonists who require urgent surgery incur major bleeding complications 18.3% more frequently than those receiving elective surgeries (21.6% versus 3.3%). 5 Acute vitamin K antagonist reversal for both indications is often accomplished by administering either fresh frozen plasma or a prothrombin complex concentrate, but consensus is lacking among international guidelines on which treatment is the optimal strategy for emergency reversal. [6] [7] [8] This systematic review compared fresh frozen plasma and prothrombin complex concentrate with a primary outcome of mortality, which is in contrast to most previous reviews that have largely relied on surrogate outcome measures (eg, INR reversal). Overall, prothrombin complex concentrate showed superior 30-day allcause mortality when used for vitamin K antagonist reversal compared with fresh frozen plasma, with an absolute risk reduction of 3.65% (number needed to treat¼28). Subgroup analyses demonstrated that the mortality benefit of prothrombin complex concentrate over fresh frozen plasma was primarily driven by observational studies, which are subject to more risk of bias than randomized controlled trials, and by studies in which the indication for vitamin K antagonist reversal was intracranial bleeding. However, this analysis may have been underpowered to detect significance within the randomized controlled trials or when vitamin K antagonist reversal was indicated by extracranial bleeding or urgent surgery. Further study may be required to increase the power of analysis for these subgroups and in randomized controlled trials. This review has several limitations. Foremost, the quality of included studies was overall low, with significant potential sources of bias. In particular, the inclusion of many observational studies increases the risk of bias inherent to such study designs (eg, recall bias, lack of a control group, selection bias, unrecognized confounding factors). Some limitations of the meta-analysis itself include the decision to pool data from the randomized controlled trials with the observational studies, relatively few studies assessing the indication for emergency surgery, outcomes were pooled and summarized as mean differences with 95% CIs. Subgroup analyses by indication for warfarin reversal, randomized controlled trial versus observational study design, and 4-versus 3-factor prothrombin complex concentrate were performed a priori. The Cochrane Collaboration's risk-of-bias tools for randomized 1 and nonrandomized 2 studies were used to assess study quality. Funnel plots were generated to assess for publication bias and heterogeneity was reported with the I 2 statistic. 
